These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31588558)

  • 21. Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC.
    Maqbool SN; Lim SC; Park KC; Hanif R; Richardson DR; Jansson PJ; Kovacevic Z
    Br J Pharmacol; 2020 May; 177(10):2365-2380. PubMed ID: 31975484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Wei Y; Li H; Qu Q
    Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
    Matevossian A; Resh MD
    Mol Cancer; 2015 Apr; 14():72. PubMed ID: 25889650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells.
    Sakunrangsit N; Ketchart W
    Eur J Pharmacol; 2020 Feb; 868():172878. PubMed ID: 31863768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
    Ayoub NM; Alkhalifa AE; Ibrahim DR; Alhusban A
    Med Oncol; 2021 Jan; 38(1):8. PubMed ID: 33449292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NADPH: Quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells.
    Pradubyat N; Sakunrangsit N; Mutirangura A; Ketchart W
    Phytomedicine; 2020 Jan; 66():153133. PubMed ID: 31790893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation.
    Zhuo Z; Zhang D; Lu W; Wu X; Cui Y; Zhang W; Zhang M
    Oncol Res; 2024; 32(6):1093-1107. PubMed ID: 38827320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-estrogenic activity of mansonone G and mansorin A derivatives.
    El-Halawany AM; Salah El Dine R; Hattori M
    Pharm Biol; 2013 Aug; 51(8):948-54. PubMed ID: 23607906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.